RNases are key enzymes in RNA metabolism and are central to both RNA processing and degradation. The nuclear 5′→3′ exoRNase XRN2 functions in processing of ribosomal and small RNAs 1-6 ; transcriptional termination 7, 8 ; clearance of aberrant precursor mRNA 9 and tRNA 10 ; degradation of microRNAs 11 ; and other pathways (reviewed in refs. 12,13). Accordingly, XRN2 is conserved across eukaryotes and is essential for the viability of yeast and worms 14, 15 . The paralogous XRN1 has a central role in mRNA degradation 16 , and both enzymes prefer 5′-monophosphorylated single-stranded RNAs as substrates [17] [18] [19] [20] .
a r t i c l e s
RNases are key enzymes in RNA metabolism and are central to both RNA processing and degradation. The nuclear 5′→3′ exoRNase XRN2 functions in processing of ribosomal and small RNAs [1] [2] [3] [4] [5] [6] ; transcriptional termination 7, 8 ; clearance of aberrant precursor mRNA 9 and tRNA 10 ; degradation of microRNAs 11 ; and other pathways (reviewed in refs. 12, 13) . Accordingly, XRN2 is conserved across eukaryotes and is essential for the viability of yeast and worms 14, 15 . The paralogous XRN1 has a central role in mRNA degradation 16 , and both enzymes prefer 5′-monophosphorylated single-stranded RNAs as substrates [17] [18] [19] [20] .
In yeast, XRN2 (Rat1p) occurs in a complex with Rat1 interacting protein (Rai1p) 18, 21 , which promotes XRN2 activity through unknown mechanisms 21, 22 . However, the metazoan Rai1p orthologs Dom3z (DXO) do not bind to their respective XRN2s 21 . In C. elegans, XRN2 instead forms a complex with the protein Partner of XRN2 (PAXT-1) 23 . Loss of PAXT-1 causes a reduction in XRN2 levels and, when worms are grown at the relatively high temperature of 26 °C, causes developmental arrest, which can be prevented by increased xrn-2 gene dosage 23 . Because paxt-1 mutations result in decreased XRN2 protein but not mRNA levels, PAXT-1 may stabilize the XRN2 protein 23 .
Although PAXT-1 is 375 amino acids long, its N-terminal 121 amino acids are sufficient for XRN2 coimmunoprecipitation, XRN2 accumulation and animal viability 23 . This portion of PAXT-1 contains a predicted domain of unknown function, DUF3469, and although PAXT-1 is not well conserved outside nematodes, DUF3469 also occurs in unrelated vertebrate and ciliate but not yeast proteins 23 .
Although it is not known whether these DUF3469-containing proteins bind XRN2, three of them, mammalian NKRF (NRF) and CDKN2AIP (CARF) and ciliate Tan1 have been observed in XRN2 complexes 3, 24, 25 . Hence, DUF3469 may function as an XTBD 23 .
We sought to elucidate XTBD structure and function. Here, we identify a core XTBD that binds XRN2, solve its crystal structure in complex with XRN2 and identify a single XTBD amino acid that makes crucial and conserved contributions to complex formation in vitro and in vivo. We demonstrate that XTBDs are general XRN2 binders in vitro and that, despite its limited sequence similarity, HsC2AIL can substitute for C. elegans PAXT-1 in vivo. Finally, we provide evidence that PAXT-1 buffers cellular RNase activity by preserving XRN2 stability in the absence of substrate.
RESULTS

Conserved binding interface of an XTBD-XRN2 complex
Previously, we have shown that the N-terminal amino acids 1-121 of C. elegans PAXT-1, which contain the XTB domain, are sufficient for XRN2 binding in vivo 23 . However, the Pfam database annotates the boundaries of XTBD as residues 7-93 (http://pfam.xfam.org/ family/xtbd/). Hence, we sought to determine the XTBD core element experimentally. On the basis of secondary-structure predictions by HHPred 26 and disorder analysis by PSIPRED Protein Analysis Workbench 27 and DisEMBL 28 , we decided to examine recombinant proteins comprising residues 1-121, 1-96 and 1-75, respectively. We found that all three polypeptides bound recombinant XRN2 equally well and bound comparably to full-length PAXT-1 ( Supplementary  Fig. 1a) . Thus, the functional XTBD is 75 amino acids long and hence is substantially smaller than previously annotated.
To gain structural information on XTBD, we expressed and purified an XRN2-PAXT-1 complex. To obtain high-qualitydiffracting protein crystals, we deleted a zinc finger-containing loop (residues 258-294), a predicted disordered region in the middle of the protein (residues 418-531) and the glycine-rich C terminus
The crystal structure confirms that PAXT-1 1-75 is the core XTBD. It binds to a large groove on XRN2, which is formed by NCS2 and PBS. XRN2 residues 645-681 form a long loop protruding from the globular core of the PBS and fold around the base of a large α-helix (residues 108-139) known as the tower domain 21 (Fig. 1b  and Supplementary Fig. 1b) . XTBD folds into a globular four-helix bundle (H1-H4) connected by three loops (L1-L3) (Fig. 1c) . H1-H3 form an antiparallel helical array, and H4 folds back on top of H2 and H3 at a 90° angle. H1 is short, comprising only six residues, whereas helices H2-H4 are much longer (10-15 residues). The four-helical bundle is mainly stabilized by hydrophobic helix-helix interactions together with additional polar interactions between side chains located on neighboring helices. One peculiarity is that L3, which connects H3 and H4, is in a completely linear conformation (Supplementary Fig. 1c) . Although a Dali search 30 against the Protein Data Bank (PDB) identified many structures with a topologically similar arrangement of three to four α-helices, either as single units or as part of a larger helical array; these differed substantially in their helix-to-helix angles and therefore represent only distant hits with low Z-scores (Z <4.5) and rather large r.m.s.d. values (>3.0 Å). Hence, it seems that the four-helix bundle of XTBD represents a structurally unique arrangement for XRN2 binding with no closely related protein structure present in the PDB.
XTBD Tyr56 is critical for complex formation
Crystal packing analysis suggested that the XTBD-XRN2∆ ZLC complex exists as a single heterodimer, and size-exclusion chromatography coupled to multiangle light scattering (SEC MALS) experiments confirmed this: the XTBD-XRN2∆ ZLC complex eluted as a monodisperse heterodimer with a measured mass of 80.9 kDa (calculated mass of 83.0 kDa) (Supplementary Fig. 2a) . Analysis of the proteinprotein interface by Proteins, Interfaces, Structures and Assemblies (PISA) 31 and Evolutionary Protein-Protein Interface Classifier (EPPIC) 32 revealed a solvent-accessible area on either protein of ~1,000 Å 2 upon complex formation. Twenty-four residues of XTBD interact with 36 residues of XRN2∆ ZLC in a hydrophobic and polar manner, and these interface residues are highly conserved, as shown by ConSurf analysis 33, 34 of both proteins (Fig. 2a) . The hydrophobic character of the interface is mainly due to XTBD residues on L1, H3 and L3 (Trp14, Ile37, Cys41, Leu52, Cys54, Tyr56 and Leu60), and it contributes to interactions with XRN2∆ ZLC residues Val553, Phe560, Pro591, Pro650, Ile652, Asp653, Pro656, Pro677 and Phe678 ( Fig. 2b and Supplementary Fig. 2b ). The formation of 13 hydrogen bonds and three salt bridges provides additional binding energy (Fig. 2c,d and Supplementary Fig. 2c ). Although the XTBD-XRN2 interface is relatively small at ~1,000 Å 2 , the complex is very stable and resists disruption by high-salt washes (data not shown) and high dilution (Supplementary Fig. 2a) .
To further dissect the XTBD-XRN2∆ ZLC interaction, we leveraged the structural information to design PAXT-1-interface pointmutant proteins, which we coexpressed with XRN2. We examined complex formation by purifying the PAXT-1 proteins through their hexahistidine (His 6 ) tags by immobilized metal affinity chromatography (IMAC). The PAXT-1 point mutations W14A and C41G did not compromise XRN2 copurification ( Fig. 2e and Supplementary Data Set 1). Less XRN2 copurified with PAXT-1 C54G, but this mutation also decreased the amount of PAXT-1 purified (Fig. 2e and Supplementary Fig. 2e ). C54G may thus disrupt protein integrity, although we note that the level of PAXT-1 C54G in bacterial lysates was comparable to that of wild-type PAXT-1 ( Supplementary  Fig. 2f ). In contrast, the Y56A mutation completely abrogated a r t i c l e s npg a r t i c l e s interaction of XTBD with XRN2 without affecting PAXT-1 levels or purification ( Fig. 2e and Supplementary Fig. 2e,f) , thus highlighting Tyr56 as a key interface residue. Because numerous side chains contribute to the total binding energy of the interface, loss of binding through a single point mutation appears surprising. However, it may be explained by the crucial role of Tyr56 in shaping the unique linear conformation of loop L3, with all seven residues of XTBD 51-57 engaged in XRN2 binding (Supplementary Fig. 2b ), contributes 33% (338 Å 2 ) buried surface area (BSA) and four hydrogen bonds to the XTBD-XRN2 interface, whereas the other 17 interacting residues together contribute the remaining 698 Å 2 BSA and nine hydrogen bonds. Mutation of Tyr56 to alanine abrogated the key constraint for the conformation of residues 51-57 by eliminating the phenol ring that is normally sandwiched between Leu45 (XTBD, H3) and Pro656 (XRN2∆ ZLC ); this tyrosine residue forms a CH-π interaction with Pro656 (XRN2∆ ZLC ) (Fig. 2c) . Through its hydroxyl group, Tyr56 also forms a hydrogen bond (2.8 Å) with the backbone carbonyl of Asp653 (XRN2∆ ZLC ) (Fig. 2c) . A second constraining residue, XTBD Cys54, engages in a hydrophobic interaction with Pro656 (XRN2∆ ZLC ) and additionally forms a weak hydrogen bond (3.8 Å) with the backbone carbonyl of Leu675 (XRN2∆ ZLC ) (Supplementary Fig. 2c ). Together, Cys54 and Tyr56 promote formation of an isolated β-bridge between backbone atoms of XTBD Glu55 and XRN2 Asp658 (Fig. 2d) . Mutation of Tyr56 to alanine and Cys54 to glycine removed the constraining side chains for this stretch and induced backbone flexibility, thus compromising all interactions between XTBD 51-57 and XRN2. The resulting loss of one-third of the BSA explains the severe consequences of these mutations. In contrast, W14A or C41G had only limited effects on the BSA and thus appear to have no major effect on complex formation in vitro.
To validate the importance of XTBD Tyr56 for XRN2 binding under physiological conditions, we used genome editing 35, 36 to create the Y56A point mutation in endogenous PAXT-1. Strikingly, when we grew the resulting paxt-1(xe29) worms at 26 °C, they arrested as L1-stage larvae, as did paxt1(0) animals (Fig. 2f) . In addition, as previously observed in paxt-1(0) animals 23 , accumulation of XRN2 was reduced, and PAXT-1 was undetectable by western blotting (Fig. 2g,  Supplementary Fig. 2d and Supplementary Data Set 1). Formally, we cannot exclude that destabilization of PAXT-1 through the Y56A mutation causes these effects. However, the protein was stable in vitro ( Fig. 2e) , as was a human XTBD protein with an analogous mutation in human cells (discussed below). Moreover, loss of XRN2 destabilizes PAXT-1 in vivo 23 . Hence, we propose that PAXT-1 depletion in vivo is a secondary consequence of its inability to bind XRN2. At any rate, our data identify Tyr56 as a critical residue for PAXT-1-mediated stabilization of XRN2 in vitro and in vivo and explain the structural basis of this importance. They also explain the high degree of conservation of this residue: In XTBDs, this position is always held by residues with aromatic side chains (tyrosine, phenylalanine and tryptophan; Fig. 1a and Supplementary Fig. 3b ), which can occupy the XRN2 Pro656 pocket via a stacking interaction.
XTBD is a general XRN2 adaptor
Although different XTBD-containing proteins occur in complexes with XRN2 (refs. 3,23-25) , these interactions have generally been examined through coimmunoprecipitation, thus leaving it unclear whether they are direct and are mediated by XTBDs. The high degree of conservation of the interaction surfaces of both XRN2 and XTBD ( Fig. 2a and Supplementary Fig. 3b,c) is as yet uncharacterized. When purifying the N-terminally His 6 -tagged XTBD proteins, we readily detected XRN2 copurification in both cases ( Fig. 3a and Supplementary Data Set 1). Similarly, human XRN2 copurified with His 6 -HsC2AIL (data not shown).
To confirm the specificity of the interaction between HsC2AIL and XRN2, we mutated C2AIL Tyr82, which corresponds to PAXT-1 Tyr56 (data not shown). We transfected human HEK293T cells with either wild-type or Y82A-mutant FLAG-and hemagglutinin (HA)-tagged HsC2AIL and immunoprecipitated the respective protein with an anti-FLAG antibody. Western blotting revealed robust coimmunoprecipitation of endogenous XRN2 with wild-type but not mutant FLAG-HA-C2AIL ( Fig. 3b and  Supplementary Data Set 1) . Finally, D. rerio XRN2 formed a stable chimeric complex with HsC2AIL, as detected by SEC (Fig. 3c) . We conclude that XTBD constitutes a general XRN2-binding domain whose mode of interaction with XRN2 is conserved across animal phylogeny.
HsC2AIL can substitute for C. elegans PAXT-1 in vivo
To validate our insights into XTBD conservation from in vitro and cell-based studies in vivo, we expressed a codon-optimized HsC2AIL single-copy transgene in paxt-1(0) mutant bearing a FLAG sequence in C. elegans. Endogenous C. elegans XRN2 coimmunoprecipitated with FLAG-HsC2AIL from worm lysates, as confirmed by western blotting (Fig. 3d and Supplementary Data Set 1) and mass spectrometry (data not shown). This confirms the formation of a chimeric complex in vivo.
Although PAXT-1 is dispensable at lower temperatures, paxt-1(0) animals arrest as L1-stage larvae when grown at 26 °C, a phenotype that is rescued by expression of PAXT-1 (ref. 23) . Strikingly, the HsC2AIL-transgenic worms similarly developed into adults and were able to produce F 2 progeny (Fig. 3e) . Hence, not only the molecular but also the developmental function of PAXT-1 can be compensated for by HsC2AIL, despite only ~35% sequence identity between their XTBDs. This result is consistent with the good correlation of the C2AIL homology model with the XTBD structure (Supplementary Fig. 3a) .
XTBD binding or substrate binding stabilizes XRN2
Previously, we have examined the influence of PAXT-1 on the enzymatic activity of XRN2 (ref. 23 ) and have found that the PAXT-1-XRN2 complex has greater activity than that of XRN2 alone over extended periods of time. However, initial velocities remain unchanged in the presence or absence of PAXT-1 (ref. 23) , and examination of Michaelis-Menten enzyme kinetics also failed to provide evidence for modulation of XRN2 activity by PAXT-1 (Supplementary Fig. 4a ). Because XRN2 protein but not mRNA levels are reduced in C. elegans lacking PAXT-1 (ref. 23 ), PAXT-1 thus appears to have a stabilizing rather than stimulatory effect on XRN2. To test this hypothesis experimentally, we monitored unfolding of recombinant XRN2 and its complex in vitro and determined the melting temperature, T m (Fig. 4a) . We found a striking shift in T m of 24 °C, from T m ≈ 31 °C for XRN2 to T m ≈ 55 °C for the PAXT-1-XRN2 complex, thus demonstrating a pronounced stabilizing activity of PAXT-1 toward XRN2. The activity largely resides in the XTBD, because the T m values of PAXT-1-XRN2, PAXT-1-XRN2∆ ZLC and XTBD-XRN2∆ ZLC complexes differed little at 55 °C, 54 °C and 53 °C, respectively. 
At 31 °C, the T m of XRN2 alone was close to the temperature at which paxt-1(0) larvae arrest development (26 °C), thus suggesting that XRN2 destabilization in vivo may occur through its unfolding and subsequent degradation. To examine the consequences of temperature increases on XRN2 activity in vitro, we assessed XRN2 destabilization at two temperatures within, or close to, the physiological range of C. elegans: 25 °C, which is the default temperature of previous activity assays, and 30 °C. From the melting curve, we estimated that 45% of XRN2 would be unfolded at 30 °C. Nonetheless, and contrary to our expectations, we found that XRN2 activity was consistently, and over extended times, higher at 30 °C than at 25 °C (Fig. 4b) .
Although an increase in temperature accelerates enzymatic reactions, according to Arrhenius's equation we expected at most a modest effect with the narrow temperature window that we used. Hence, we considered that XRN2 might be unexpectedly stable under the conditions of the assay, possibly because of substrate binding. To test this, we examined XRN2 thermal stability in the absence and presence of the 30-mer RNA substrate used for catalytic assays. The results revealed a stabilizing effect of the substrate, which increased the T m by 2 °C, to ~33 °C (Fig. 4c) . Although the effect was small relative to that seen for PAXT-1, it was above the 1 °C threshold previously proposed to be relevant 40 , and it occurred reproducibly at two different substrate concentrations (data not shown). Moreover, it was highly specific, because inclusion of tRNA, which is a poor XRN2 substrate because of its high secondary structure and paired 5′-terminal nucleotides 18, 20 , did not increase the thermal stability of XRN2. We conclude that substrate binding can stabilize XRN2.
To test whether the stabilizing effect of substrate binding explained the unexpectedly robust activity of XRN2 at 30 °C, we preincubated either XRN2 alone or a PAXT-1-XRN2 complex in buffer for 5 min at this temperature before adding substrate. Whereas the PAXT-1-XRN2 complex exhibited robust activity under these conditions, the activity of XRN2 alone was compromised ( Fig. 4d and Supplementary  Fig. 4b) . Hence, PAXT-1 can preserve activity of XRN2 in the absence of substrate.
XRN2 stability depends on structural integrity of the PBS
To understand the interaction of XRN2 with substrate, we superimposed the XRN1-RNA substrate complex (PDB 2Y35 (ref. 20)) onto the XTBD-XRN2 structure. This revealed a crucial role of the PBS-protruding loop in substrate binding, in which its Trp670 base-stacks with three unpaired 5′-terminal nucleotides and His60 of α-helix 2 (Fig. 4e) . Moreover, Trp670 in XRN2, like Trp540 in XRN1 (ref. 20) , functions in concert with the N-terminal α-helix 1 to sterically restrict access of single-stranded RNA to the active site. A sulfate ion from the crystallization buffer of the XTBD-XRN2 complex occupies the precise position of the 5′ phosphate of the XRN1-RNA substrate complex (Fig. 4e) , thus confirming conservation of the mode of substrate binding.
From the structures of the two complexes, it is thus evident that both substrate and PAXT-1 bind to the PBS. To determine whether this binding might affect PBS structure, we compared the PBSs from these two complexes to that of K. lactis XRN1, which was previously crystallized in the absence of both substrate and additional proteins (PDB 3PIF 29 ). Strikingly, whereas the PBS is fully structured in XRN2-XTBD and Drosophila XRN1-RNA complexes, it is heavily disordered in the structure of K. lactis XRN1, and the domain could not be entirely built in the crystallographic model (Fig. 4f) . Hence, although they do not constitute proof, these structures are consistent 
a r t i c l e s
with the notion that stabilization of XRN2 is achieved through maintenance of the integrity of the PBS, which can be accomplished by both XTBD binding and substrate binding (Fig. 4f) .
DISCUSSION
On the basis of the recurring identification of XTBD (DUF3469)-containing proteins in complexes that also contain XRN2 (refs. 3,23-25), we have previously hypothesized that XTBD might mediate XRN2 binding 23 . Here, we tested this notion and demonstrate that a core XTBD, substantially smaller than initially predicted, mediates binding to XRN2. Chimeric interactions between XTBDcontaining proteins and XRN2 from different species in vivo and in vitro confirmed the generality of this finding. Although XRN2 and its paralog XRN1 are highly similar, notably in the PAXT-1-binding groove (Supplementary Fig. 1e) , binding of PAXT-1 to XRN1 is disfavored: the NCS2 of XRN1 extends further into the groove than that of XRN2, thus suggesting a steric clash with XTBD ( Supplementary  Fig. 1e ). This possibility is consistent with results from coimmunoprecipitation experiments revealing a specific interaction of PAXT-1 with XRN2 but not XRN1 (ref. 23) . Hence, XTBD is a general and specific XRN2 binding domain. Interestingly, its binding to XRN2 is entirely distinct from that of Rai1p (Supplementary Fig. 1d and ref. 21 ), a finding that may explain the distinct functions of the two proteins, such as the promotion of XRN2 activity by Rai1p 21, 22 versus the stabilization of XRN2 by PAXT-1 (ref. 23 and this study).
Although PAXT-1 is the only XTBD-containing protein in C. elegans, many vertebrates have three such predicted XTBD proteins: CDKN2AIP, C2AIL and NKRF 23 . Outside their XTBDs, these proteins exhibit little sequence homology, and their cellular functions appear distinct: mammalian NKRF was identified as a transcriptional repressor 41 , CDKN2AIP appears to function as an activator of p53 (refs. 37-39) , and C2AIL currently has no known function. However, the strong interactions that we observed between XTBDs and XRN2 imply that all of these proteins exert at least part of their functions with or through XRN2. The ability to uncouple these proteins from XRN2 through a single point mutation now enables testing of this notion for each of these proteins.
The stable and heterodimeric binding between XRN2 and XTBD also implies that vertebrate XRN2 exists in multiple separate and noninterconvertible complexes, thus potentially diversifying XRN2 functions. Different binding partners may endow XRN2 with distinct catalytic activities, facilitate differential regulation of XRN2 through distinct subunits or recruit XRN2 to distinct cellular locations. Experiments on human U-2 OS osteosarcoma cell lines have provided circumstantial evidence for the latter, because XRN2 immunofluorescence staining has been observed in both the nucleus and nucleoplasm, whereas NKRF locates to the nucleolus, from which the nucleoplasmic CDKN2AIP appears to be excluded 42 . Because the phosphorylation status of NKRF may modulate the interaction between NKRF and XRN2 (ref. 43 ), it will be interesting to determine whether NKRF phosphorylation also affects localization of NKRF and/or XRN2.
According to such a model of functional specialization of XRN2 complexes, XTBD serves to bridge XRN2 with specific protein domains that provide additional functionalities. Because a complex of XRN2 with full-length PAXT-1 did not crystallize, we do not know what such functions might be in the case of the PAXT-1 C-terminal sequence, which is conserved across nematodes. Speculatively, it may modulate XRN2 activity or block access of specific substrates to the XRN2 active site. This is because the structure of the XRN2-XTBD complex implies that the PAXT-1 C terminus would be located 27 and DisEMBL 28 suggests that the C terminus is structured (data not shown). Because we have thus far been unable to observe regulation of XRN2 activity by PAXT-1 in vitro, such functions might require specific substrates or conditions that remain to be identified. Alternatively, the PAXT-1 C terminus might modulate PAXT-1 stability or binding to XRN2.
In support of a more specialized role of the PAXT-1 C terminus, this region is dispensable for C. elegans viability 23 . Together with the ability of heterologous HsC2AIL to substitute for PAXT-1 in vivo, this finding implies functions of XTBD beyond that of a passive XRN2 adaptor. We propose that one such function might be stabilization of XRN2 by promoting folding of its PBS segment. The T m is a measure of a protein's thermal stability and depends on numerous molecular parameters such as the amino acid composition, surface hydrophobicity, number of hydrogen bonds and labile secondary structures such as loops 44 . Upon XTBD binding, 13 hydrogen bonds are formed, a hydrophobic patch is covered, and the flexibility of the PBS loop is reduced. Decreased thermal stability of XRN2 in the absence of XTBD in vitro may then reflect decreased half-life in vivo [45] [46] [47] , because even partially unfolded proteins exhibit increased susceptibility to proteolysis 47, 48 . These results then explain how PAXT-1-XTBD binding increases XRN2 levels in vivo.
Although PAXT-1 is expressed throughout C. elegans development 23 , its loss causes defects only at specific stages: when paxt-1(0) mutant animals are shifted to the restrictive temperature of 26 °C during the L4 stage, they continue development through adulthood and produce F 1 progeny, which, however, arrest at the L1 stage 23 . This delayed effect does not simply reflect slow depletion of XRN2, because L1-stage arrest of F 1 animals also occurs if parental animals are shifted to 26 °C during their L1 stage 23 . Moreover, although animals may conceivably be more dependent on XRN2 activity during some developmental stages than others, developmental arrest can be induced in virtually any stage upon direct inactivation of XRN2 (ref. 15) . Hence, we speculate that it is the stability of XRN2 that varies with developmental stage. Specifically, substrate binding may confer some stability to XRN2, and the stabilizing activity of PAXT-1 may be more important when substrate levels are low. Thus, a key function of PAXT-1 may be to preserve, rather than promote, XRN2 activity, thereby guarding enzyme not bound by substrate against decay and causing a constant pool of active protein to be retained.
METHODS
Methods and any associated references are available in the online version of the paper. Animal experiments. Experiments were not blinded or randomized; no statistical calculations were performed to predetermine sample size. Animal procedures were approved by the Veterinary Department of the Canton Basel-Stadt (Switzerland).
Protein expression and purification. Expression constructs were cloned into a modified biscistronic pCOLADuet vector from Novagen. XTBD-containing constructs were cloned into the first multiple cloning site (MSC) and thus N-terminally extended by a hexahistidine (His 6 ) tag followed by a tobacco etch virus protease (TEV)-cleavage site, whereas the XRN2 constructs in the second MSC remain untagged. All constructs were expressed in E. coli BL21(DE3). Cells were lysed by sonication, and the lysate was cleared by centrifugation. Immobilized metal affinity chromatography (IMAC) slurry (Qiagen) was used to bind the His 6 tag of the target protein. Next, proteins were eluted through cleavage by TEV (homemade) 50 . IMAC was repeated, and the unbound fraction was collected, diluted and purified on a Mono Q 5/50 GL (GE Healthcare) anion-exchange column. Positive fractions were pooled, filtered with a Millex-GV 0.22-µm filter and loaded onto a Superdex 200 HiLoad 16/600 (GE Healthcare) column. Finally, the target fractions were collected and concentrated with Millipore Amicon Ultra centrifugal filter concentrators with suitable pore size.
Incorporation of selenomethionine was performed as described by Molecular Dimensions' SelenoMethionine media kit, with E. coli B834(DE3).
Crystallization, data collection, and structure solution. Protein crystallization was carried out at 20 °C with the sitting-drop vapor-diffusion method with a Phoenix robot (Art Robbins) dispensing 300-nl drops (100 nl crystallization buffer and 200 nl protein solution). XRN2∆ ZLC −XTBD crystals, obtained in 2 M ammonium sulfate, 0.1 M Bis-Tris, pH 6.5, or 0.1 M Tris, pH 8.5, were harvested and flash cooled in liquid nitrogen after cryoprotection with 3.2 M ammonium sulfate, 0.1 M Bis-Tris, pH 6.5, or 0.1 M Tris, pH 8.5. The highest-resolution data were obtained with a selenomethionine-derivative crystal diffracting to 2.85 Å (λ = 0.97796; T = 100 K) at the SLS PX-II beamline (Villigen, Switzerland) and belonged to space group P2 1 2 1 2 1 with six XRN2∆ ZLC -XTBD heterodimers in the asymmetric unit. Diffraction data were integrated and scaled with the XDS program package 51 , and the structure was solved by the molecular replacement method with PHASER 52 with an XRN2 homology model consisting of the exonuclease core as search model. Phases from this solution were calculated and used for automatic model building with BUCCANEER 53 . The XRN2∆ ZLC -XTBD structure was further improved by the crystallographic simulated annealing routine followed by grouped B-factor refinement in PHENIX 54 , several rounds of manual rebuilding in COOT 55 and refinement in PHENIX and BUSTER (http:// www.globalphasing.com/buster/). Noncrystallographic-symmetry restraints were used throughout the structure solution and refinement process. NCS copies of XRN2∆ ZLC and XTBD were highly similar, with r.m.s. deviations between 0.456 and 0.597 Å (Cα) for XRN2∆ ZLC (chain A related to all other XRN2∆ ZLC chains present in the asymmetric unit) and 0.313 and 0.741 Å (Cα) for XTBD (chain B related to all other XTBD chains present in the asymmetric unit). Model building and validation was carried out by use of anomalous difference Fourier electron density maps to locate selenomethionine positions. The final structure was validated with Coot (Ramachandran-plot statistics: allowed, 99.6%; outliers, 0.4%) and the wwPDB Validation Server (http://wwpdbvalidation.wwpdb.org/validservice/). Atomic coordinates and structure factors for the XRN2∆ ZLC -XTBD complex have been deposited in the PDB under accession code PDB 5FIR. Structural images for figures were prepared with PyMOL version 1.3r1 (http://www.pymol.org/).
Sequence logo.
The profile hidden Markov model (HMM) of DUF3469 from Pfam was exported and uploaded to http://skylign.org/ 49 . For concise representation, the following parameters were set: (i) alignment Processing to 'Create HMM -remove mostly-empty columns' , (ii) fragment handling to ' Alignment sequences are full length' and (iii) letter height to 'Information Content -Above Background' . The resulting logo was exported without showing the gap parameters.
Thermal shift assay. In a 20-µl reaction, 2 µg of assayed protein was mixed with Protein Thermal Shift Dye and Buffer from Applied Biosystems to a final concentration of 1×. In the presence of RNA substrate, however, 1 µg of protein was used instead to reduce the otherwise high concentrations of RNA. Purified yeast tRNA (Ambion) or a 30-mer XRN2 substrate identical to that used in the kinetic assays (described below) were used when examining the effect of substrate binding. The reactions were prepared in a 96-well MicroAmp optical microplate at 4 °C, which was sealed with MicroAmp Optical Adhesive Film. After centrifugation for 25 s at 1,000g, the plate was read in a StepOnePlus real-time PCR system with a melting-curve program from 25-99 °C. No normalizing quencher was used, and reactions were run in triplicate. Raw data were exported and plotted with Microsoft Excel. The sigmoidal part of the curve was fit to the Boltzmann equation (equation (1)) with nonlinear regression by maximizing R 2 and varying T m and C, and the melting point, T m , was calculated as the inflection point. The resulting function was normalized to 1 and plotted (as described below). Raw data were also normalized to 1 and plotted as dashed lines. In addition, XRN2, XRN2 + tRNA, and XRN2 + RNA curves and values were rescaled by a factor of 1.9, 1.3, and 1.8, respectively, for concise representation. Real-time exonuclease activity assay and kinetic analysis. The kinetic assay was performed as described in ref. 56 with the following modifications. The RNA-DNA duplex substrate, in which the RNA was FAM labeled, and the DNA carried a quencher, was diluted with a four-fold excess of unlabeled 5′-phosphorylated let-7, which increased the dynamic range of the qPCR system. 300 fmol enzyme was assayed with varying concentrations of total substrate (sum of RNA-DNA duplex and let-7) in an excess of 5 to 200 fold. Each kinetic reaction was run in triplicate and yielded one data point. After each data point was normalized to its baseline, the initial linear phase from 0 to 180 s was fitted by linear regression. The slope of this function equals the velocity at the corresponding substrate concentration, [S] . Furthermore the average of three velocities was plotted over Genome editing of C. elegans with CRISPR-Cas9. A suitable site for a 20-ntlong sgRNA was identified by considering the availability of a PAM site to create a double-strand break on the paxt-1 gene. Two complementary oligonucleotides were hybridized and cloned by Gibson assembly 58 into pIK111, a derivative of the PU6øsgRNA backbone 59, 60 . Furthermore, a 100-nt DNA single-stranded repair oligo was designed with the desired point mutation and a silent mutation at the sgRNA-binding site. A CRISPR coconversion mix (analogous to that in (1) (1) (2) (2) npg
